Premium
[P4–205]: FIXED‐DOSE COMBINATION OF DONEPEZIL HYDROCHLORIDE AND MEMANTINE HYDROCHLORIDE FOR TREATMENT OF MODERATE TO SEVERE ALZHEIMER'S DISEASE
Author(s) -
Zung Stevin Parreira,
CupermanPohl Thais,
Morais Douglas Costa,
Marques de Oliveira Rosyanne Michele,
Bernes Edson Antonio
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.2073
Subject(s) - donepezil , bioavailability , bioequivalence , memantine , concomitant , pharmacology , medicine , pharmacokinetics , dose , fixed dose combination , dementia , disease
educational resources and online tools, including the Health-eBrain Study for AD caregivers, which includes a case management intervention to reduce stress. USA2 networks conduct outreach, with a focus on underrepresented minorities. Results:Over 30,000 participants are enrolled in AD-PCPRN through BHR; 48% have returned for longitudinal follow-up. Over 10,00 have been referred to, and 757 enrolled in, AD clinical studies. The cohort has 13% nonCaucasian participants, including 4% African Americans and 3% Latinos. USA2 outreach recruited 15% African Americans and 6% Latinos. Of all participants, 9536 (30%) are likely to be eligible for AD trials: 23% for preclinical trials, 6% for prodromal trials, and 1.4% for dementia trials. Over 250 AD caregivers and 2100 study partners have enrolled in BHR, and 212 AD caregivers have enrolled in the Health-eBrain Study. Conclusions: Innovation in the use of Internet technologies and patientand caregiver-